Nektar Therapeutics

NKTR

US6402681083

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
1.29 ^USD	-0.77%		+4.03%	+128.32%

07-01	Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Comp Value Index	CI
07-01	Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Completeness Index	CI

Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Microcap Value Index

July 30, 2024

Latest news about Nektar Therapeutics

Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Comp Value Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Completeness Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 2000 Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 3000E Value Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 3000E Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Microcap Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 2500 Value Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 3000 Value Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 2000 Value Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 2000 Dynamic Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Microcap Value Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 2500 Index	06-30	CI
Nektar Therapeutics(NasdaqCM:NKTR) added to Russell 3000 Index	06-30	CI
Transcript : Nektar Therapeutics Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM	06-10
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M	05-09	MT
Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024	05-09	CI
Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024	05-09
Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	04-24	CI
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	03-18	CI
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	03-05	MT
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating	03-05	MT
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	03-05	CI
Transcript : Nektar Therapeutics, Q4 2023 Earnings Call, Mar 04, 2024	03-04
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	03-04	CI

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the bodyâs immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the bodyâs innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nektar Therapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.29 USD

Average target price

1.6 USD

Spread / Average Target

+24.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEKTAR THERAPEUTICS	+128.32%	237M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals